MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$31,627K
Free Cash flow
$15,142K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Increase in accrued expenses
Proceeds from exercise of share ...
(increase) decrease in prepaymen...
Others
Negative Cash Flow Breakdown
Sg&a expenses-Other Selling Gene...
PRAMEPrograms
Other Clinical And Pre Clinical ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
115,927
106,677
104,478
103,693
Cost of revenue from sale of therapies
1,088
434
2,703
4,255
PRAMEPrograms
20,091
21,214
22,644
97,933
Tebentafusp Programs
11,863
8,239
10,628
48,603
Infectious Disease Programs
525
846
2,373
6,807
Other Clinical And Pre Clinical Costs
16,352
8,493
17,681
68,519
R&d expenses-External RD
48,831
38,792
53,326
221,862
R&d expenses-Salaries And Other Employee Related Cost
14,258
14,140
14,016
59,832
Sg&a expenses-Salaries And Other Employee Related Cost
13,906
13,090
9,574
64,128
Sg&a expenses-Other Selling General And Administrative Expenses
23,347
21,065
26,844
103,913
Other segment (expense) income, net
15,305
6,185
28,075
44,124
Net income (loss)
-808
12,971
-30,060
-177
Share-based compensation expense
9,404
6,302
8,339
9,837
Depreciation
1,026
948
834
798
Unrealized foreign exchange gains, net
-808
3,490
-3,844
9,622
Unrealized gains on marketable securities
3,071
1,776
4,504
5,062
Loss on loan extinguishment
-
-
0
-
Non-cash lease expense
610
627
667
567
Deferred income taxes
-
-
14,790
-
Other
-546
-534
-537
-527
Increase in accounts receivable
14,621
7,930
-1,994
5,989
(increase) decrease in prepayments and other current assets
-2,097
18,772
1,016
6,089
Increase (decrease) in accounts payable
-4,803
5,974
1,418
-287
Increase in accrued expenses
27,001
-8,303
-22,031
15,133
Decrease in deferred revenue
-146
-146
-144
-146
Decrease in operating lease liabilities
-1,360
-864
-2,617
1,052
Decrease in other operating assets
755
-150
4,706
4,998
Decrease in other operating liabilities
-
-
0
0
Net cash provided by operating activities
15,928
-13,775
-32,655
-4,456
Proceeds from sale of property, plant and equipment
-
-
0
-
Purchase of marketable securities
0
-
0
0
Proceeds from sale of marketable securities
0
6,000
2,000
6,000
Purchase of property and equipment
786
1,781
2,880
748
Net cash provided by (used in) investing activities
-786
4,219
-880
5,252
Proceeds from issue of ordinary shares, net
-
-
0
-
Proceeds from exercise of share options
16,485
656
4,284
1,866
Loan repayments
-
-
0
-
Debt prepayments and extinguishments
-
-
0
-
Proceeds from issue of convertible senior notes
-
-
-
0
Non-current interest-bearing loan received
-
-
0
-
Debt issuance payments
-
-
0
0
Net cash provided by financing activities
16,485
656
4,284
1,866
Increase in cash and cash equivalents
31,627
-8,900
-29,251
2,662
Net foreign exchange difference on cash held
618
-6,134
-1,453
28,112
Cash and cash equivalents at beginning of period
452,675
467,709
498,413
455,731
Cash and cash equivalents at end of period
484,920
452,675
467,709
498,413
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
share options
$16,485K
(164.99%↑ Y/Y)
Increase in accrued
expenses
$27,001K
(18.49%↑ Y/Y)
Share-based compensation
expense
$9,404K
(-51.83%↓ Y/Y)
(increase) decrease in
prepayments and other...
-$2,097K
(-474.52%↓ Y/Y)
Depreciation
$1,026K
(-37.21%↓ Y/Y)
Unrealized foreign
exchange gains, net
-$808K
(-233.11%↓ Y/Y)
Non-cash lease expense
$610K
(-45.24%↓ Y/Y)
Other
-$546K
(47.95%↑ Y/Y)
Net cash provided by
financing activities
$16,485K
(164.99%↑ Y/Y)
Net cash provided by
operating activities
$15,928K
(-39.66%↓ Y/Y)
Canceled cashflow
$25,564K
Total revenue
$115,927K
(-39.57%↓ Y/Y)
Increase in cash and cash
equivalents
$31,627K
(165.59%↑ Y/Y)
Canceled cashflow
$786K
Increase in accounts
receivable
$14,621K
(337.62%↑ Y/Y)
Increase (decrease) in
accounts payable
-$4,803K
(-33.90%↓ Y/Y)
Unrealized gains on
marketable securities
$3,071K
(-69.78%↓ Y/Y)
Decrease in operating
lease liabilities
-$1,360K
(-157.58%↓ Y/Y)
Net income (loss)
-$808K
(84.69%↑ Y/Y)
Decrease in other
operating assets
$755K
(121.41%↑ Y/Y)
Decrease in deferred
revenue
-$146K
(-50.52%↓ Y/Y)
Canceled cashflow
$115,927K
Net cash provided by
(used in) investing...
-$786K
(96.21%↑ Y/Y)
R&d
expenses-External RD
$48,831K
(157.04%↑ Y/Y)
Sg&a expenses-Other
Selling General And...
$23,347K
(154.40%↑ Y/Y)
Other segment
(expense) income, net
$15,305K
(186.32%↑ Y/Y)
R&d
expenses-Salaries And Other...
$14,258K
(159.53%↑ Y/Y)
Sg&a
expenses-Salaries And Other...
$13,906K
(155.52%↑ Y/Y)
Cost of revenue from
sale of therapies
$1,088K
(158.15%↑ Y/Y)
Purchase of property and
equipment
$786K
(10.39%↑ Y/Y)
PRAMEPrograms
$20,091K
(152.89%↑ Y/Y)
Other Clinical And Pre
Clinical Costs
$16,352K
(161.74%↑ Y/Y)
Tebentafusp Programs
$11,863K
(164.45%↑ Y/Y)
Infectious Disease
Programs
$525K
(119.23%↑ Y/Y)
Buy us a coffee
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)